Sun Pharma to acquire Organon in $11.75B cash deal, boosting biosimilars
Sun Pharma to acquire Organon in $11.75B cash deal, boosting biosimilars
Sun Pharma strikes an $11.75 billion all-cash deal for Organon, boosting its innovative medicines and biosimilars footprint and signaling a major shift in global pharma strategy.
Sun Pharmaceutical Industries has announced an all-cash acquisition of Organon & Co. valued at $11.75 billion, in a move that could reshape the global pharmaceutical landscape. The deal values Organon at $14 per share and will be effected by a merger of Organon with a Sun Pharma subsidiary, with Organon set to survive the merger. The closing is expected in early 2027, subject to customary conditions.
Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks, underscoring the company’s confidence in the strategic fit and long-term value of the combined business. The deal is designed to strengthen Sun Pharma’s innovative medicines pipeline while giving it a stronger foothold in biosimilars and women’s health, areas where Organon has substantial expertise and a broad product portfolio.
Organon brings a portfolio of more than 70 products spanning women’s health and general medicines, including a range of biosimilars. The U.S.-based company operates across a global footprint and has six manufacturing facilities across the European Union and emerging markets. Its largest markets include the United States, Europe, China, Canada and Brazil, among others.
The strategic intent behind the acquisition is to position Sun Pharma as a top-tier player in both branded and generic medicines and to accelerate entry into biosimilars as a leading global player. Organon’s stakeholders, portfolio and global relationships are expected to complement Sun Pharma’s existing strengths and unlock long-term value for shareholders.
The announcement also highlights that the combined entity would leverage Organon’s leadership in women’s health with Sun Pharma’s scale in innovative therapies, potentially broadening access to advanced medicines in multiple markets. Sun Pharma, based in Mumbai, has been pursuing aggressive growth strategies, and this cash deal signals a bold step toward expanding its global reach and product portfolio. Sun Pharma’s stock movement in response to the news reflected investor optimism, with shares rising on the trading day following the announcement.
Overall, the deal marks a significant milestone for Sun Pharma as it seeks to become a top-10 global player in biosimilars and broaden its presence in women’s health and innovative medicines, with the potential to reshape competitive dynamics in the years ahead.
